| 316.01 -6.07 (-1.88%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 387.21 | 1-year : | 452.26 |
| Resists | First : | 331.51 | Second : | 387.21 |
| Pivot price | 318.31  |
|||
| Supports | First : | 295.2 | Second : | 272.75 |
| MAs | MA(5) : | 324.33 |
MA(20) : | 314.82 |
| MA(100) : | 297.2 |
MA(250) : | 315.78 |
|
| MACD | MACD : | 8.9 |
Signal : | 9.2 |
| %K %D | K(14,3) : | 70.3 |
D(3) : | 82.1 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 385.22 | Low : | 253.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ONC ] has closed above bottom band by 42.7%. Bollinger Bands are 29% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 321.54 - 323.47 | 323.47 - 324.91 |
| Low: | 306.48 - 309.02 | 309.02 - 310.9 |
| Close: | 312.65 - 316.43 | 316.43 - 319.23 |
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
Fri, 31 Jul 2026
65,456 Shares in BeOne Medicines Ltd. - Sponsored ADR $ONC Bought by Renaissance Technologies LLC - MarketBeat
Thu, 30 Jul 2026
BeOne Medicines: Owning The Full B-Cell Treatment Sequence - Seeking Alpha
Wed, 29 Jul 2026
ADAR1 Capital Management LLC Makes New Investment in BeOne Medicines Ltd. - Sponsored ADR $ONC - MarketBeat
Tue, 28 Jul 2026
John Oyler Sells 61,397 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
Mon, 27 Jul 2026
Nomura Adjusts BeOne Medicines Price Target to $454.75 From $442.91, Maintains Buy Rating - marketscreener.com
Wed, 22 Jul 2026
A BeOne Founder Sold $34.6 Million in Stock but Keeps a Massive Position - The Motley Fool
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 95 (M) |
| Held by Insiders | 7.83e+007 (%) |
| Held by Institutions | 17.2 (%) |
| Shares Short | 902 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 4.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 970.79 |
| Profit Margin | 8.9 % |
| Operating Margin | 16.5 % |
| Return on Assets (ttm) | 5.9 % |
| Return on Equity (ttm) | 12.4 % |
| Qtrly Rev. Growth | 35.5 % |
| Gross Profit (p.s.) | 1.03469e+010 |
| Sales Per Share | 1.17143e+010 |
| EBITDA (p.s.) | 1.68447e+009 |
| Qtrly Earnings Growth | 16 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 1,280 (M) |
| PE Ratio | 71.33 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | 3.61 |
| Dividend | 0 |
| Forward Dividend | 926990 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|